Harrow Net Income From Continuing Ops vs Cost Of Revenue Analysis

HROWL Stock

USD 25.43 0.08 0.32%

Harrow Health financial indicator trend analysis is much more than just examining Harrow Health 8625 latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Harrow Health 8625 is a good investment. Please check the relationship between Harrow Health Net Income From Continuing Ops and its Cost Of Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Harrow Health 8625 Net Income From Continuing Ops account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.

The correlation between Harrow Health's Net Income From Continuing Ops and Cost Of Revenue is -0.72. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Harrow Health 8625, assuming nothing else is changed. The correlation between historical values of Harrow Health's Net Income From Continuing Ops and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of Harrow Health 8625 are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income From Continuing Ops i.e., Harrow Health's Net Income From Continuing Ops and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.72

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Net Income From Continuing Ops

Cost Of Revenue

Cost of Revenue is found on Harrow Health 8625 income statement and represents the costs associated with goods and services Harrow Health provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Harrow Health's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Harrow Health 8625 current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.At this time, Harrow Health's Selling General Administrative is quite stable compared to the past year. Tax Provision is expected to rise to 4,830 this year, although the value of Sales General And Administrative To Revenue will most likely fall to 0.73.

	2021	2022	2023	2024 (projected)
Total Revenue	72.5M	88.6M	130.2M	136.7M
Depreciation And Amortization	2.4M	3.7M	12.3M	13.0M

Total Revenue Depreciation And Amortization

Harrow Health fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Accounts Payable	Non Current Liabilities Total	Other Current Assets	Property Plant And Equipment Net	Non Current Assets Total	Non Currrent Assets Other	Short Long Term Debt Total	Current Deferred Revenue	Short Term Debt	Net Receivables	Good Will	Short Term Investments	Inventory
Total Assets		0.92	0.98	0.94	0.95	-0.82	0.86	0.9	0.77	0.92	1.0	0.97	0.6	0.95	0.99	0.66	0.48	0.98	-0.27	0.99	0.27	-0.11	0.96	-0.3	0.24	0.99
Other Current Liab	0.92		0.94	0.89	0.98	-0.67	0.63	0.66	0.61	0.81	0.91	0.8	0.4	0.79	0.89	0.35	0.27	0.98	-0.28	0.9	0.13	-0.13	0.99	-0.22	0.16	0.88
Total Current Liabilities	0.98	0.94		0.95	0.96	-0.82	0.77	0.83	0.77	0.93	0.97	0.92	0.6	0.94	0.95	0.58	0.49	0.98	-0.33	0.96	0.34	-0.01	0.98	-0.18	0.29	0.97
Total Stockholder Equity	0.94	0.89	0.95		0.89	-0.75	0.73	0.83	0.78	0.9	0.91	0.9	0.58	0.88	0.89	0.53	0.49	0.93	-0.17	0.89	0.25	0.04	0.92	-0.34	0.44	0.92
Net Debt	0.95	0.98	0.96	0.89		-0.76	0.67	0.73	0.72	0.87	0.94	0.85	0.54	0.84	0.93	0.41	0.43	0.98	-0.32	0.94	0.22	-0.05	0.97	-0.22	0.26	0.93
Retained Earnings	-0.82	-0.67	-0.82	-0.75	-0.76		-0.74	-0.82	-0.94	-0.96	-0.82	-0.84	-0.84	-0.85	-0.81	-0.61	-0.79	-0.76	0.21	-0.82	-0.3	-0.1	-0.72	-0.07	-0.38	-0.87
Cash	0.86	0.63	0.77	0.73	0.67	-0.74		0.95	0.66	0.78	0.88	0.94	0.56	0.9	0.9	0.9	0.45	0.75	-0.17	0.89	0.26	-0.27	0.73	-0.36	0.04	0.85
Cash And Short Term Investments	0.9	0.66	0.83	0.83	0.73	-0.82	0.95		0.82	0.87	0.9	0.98	0.71	0.93	0.91	0.85	0.63	0.78	-0.14	0.9	0.33	-0.07	0.75	-0.38	0.34	0.91
Common Stock Shares Outstanding	0.77	0.61	0.77	0.78	0.72	-0.94	0.66	0.82		0.93	0.76	0.82	0.86	0.8	0.75	0.53	0.85	0.7	-0.07	0.75	0.27	0.2	0.65	-0.07	0.64	0.84
Other Stockholder Equity	0.92	0.81	0.93	0.9	0.87	-0.96	0.78	0.87	0.93		0.91	0.92	0.77	0.92	0.9	0.61	0.7	0.88	-0.22	0.91	0.3	0.08	0.86	-0.08	0.43	0.95
Total Liab	1.0	0.91	0.97	0.91	0.94	-0.82	0.88	0.9	0.76	0.91		0.97	0.6	0.95	1.0	0.68	0.48	0.97	-0.29	1.0	0.28	-0.15	0.96	-0.28	0.19	0.98
Total Current Assets	0.97	0.8	0.92	0.9	0.85	-0.84	0.94	0.98	0.82	0.92	0.97		0.67	0.97	0.97	0.79	0.58	0.89	-0.22	0.97	0.32	-0.09	0.87	-0.35	0.29	0.97
Common Stock	0.6	0.4	0.6	0.58	0.54	-0.84	0.56	0.71	0.86	0.77	0.6	0.67		0.66	0.59	0.51	0.91	0.51	-0.12	0.6	0.4	0.33	0.46	-0.03	0.58	0.68
Accounts Payable	0.95	0.79	0.94	0.88	0.84	-0.85	0.9	0.93	0.8	0.92	0.95	0.97	0.66		0.95	0.81	0.57	0.89	-0.33	0.95	0.43	-0.08	0.87	-0.2	0.26	0.96
Non Current Liabilities Total	0.99	0.89	0.95	0.89	0.93	-0.81	0.9	0.91	0.75	0.9	1.0	0.97	0.59	0.95		0.7	0.47	0.96	-0.28	1.0	0.26	-0.18	0.94	-0.31	0.16	0.98
Other Current Assets	0.66	0.35	0.58	0.53	0.41	-0.61	0.9	0.85	0.53	0.61	0.68	0.79	0.51	0.81	0.7		0.45	0.51	-0.29	0.68	0.46	-0.16	0.5	-0.24	0.03	0.68
Property Plant And Equipment Net	0.48	0.27	0.49	0.49	0.43	-0.79	0.45	0.63	0.85	0.7	0.48	0.58	0.91	0.57	0.47	0.45		0.38	-0.1	0.47	0.4	0.48	0.33	0.01	0.69	0.6
Non Current Assets Total	0.98	0.98	0.98	0.93	0.98	-0.76	0.75	0.78	0.7	0.88	0.97	0.89	0.51	0.89	0.96	0.51	0.38		-0.3	0.96	0.21	-0.12	1.0	-0.25	0.19	0.95
Non Currrent Assets Other	-0.27	-0.28	-0.33	-0.17	-0.32	0.21	-0.17	-0.14	-0.07	-0.22	-0.29	-0.22	-0.12	-0.33	-0.28	-0.29	-0.1	-0.3		-0.28	-0.44	-0.12	-0.32	-0.13	0.07	-0.3
Short Long Term Debt Total	0.99	0.9	0.96	0.89	0.94	-0.82	0.89	0.9	0.75	0.91	1.0	0.97	0.6	0.95	1.0	0.68	0.47	0.96	-0.28		0.26	-0.16	0.95	-0.3	0.18	0.98
Current Deferred Revenue	0.27	0.13	0.34	0.25	0.22	-0.3	0.26	0.33	0.27	0.3	0.28	0.32	0.4	0.43	0.26	0.46	0.4	0.21	-0.44	0.26		0.52	0.21	0.28	0.32	0.31
Short Term Debt	-0.11	-0.13	-0.01	0.04	-0.05	-0.1	-0.27	-0.07	0.2	0.08	-0.15	-0.09	0.33	-0.08	-0.18	-0.16	0.48	-0.12	-0.12	-0.16	0.52		-0.12	0.22	0.62	-0.02
Net Receivables	0.96	0.99	0.98	0.92	0.97	-0.72	0.73	0.75	0.65	0.86	0.96	0.87	0.46	0.87	0.94	0.5	0.33	1.0	-0.32	0.95	0.21	-0.12		-0.25	0.15	0.93
Good Will	-0.3	-0.22	-0.18	-0.34	-0.22	-0.07	-0.36	-0.38	-0.07	-0.08	-0.28	-0.35	-0.03	-0.2	-0.31	-0.24	0.01	-0.25	-0.13	-0.3	0.28	0.22	-0.25		-0.13	-0.27
Short Term Investments	0.24	0.16	0.29	0.44	0.26	-0.38	0.04	0.34	0.64	0.43	0.19	0.29	0.58	0.26	0.16	0.03	0.69	0.19	0.07	0.18	0.32	0.62	0.15	-0.13		0.32
Inventory	0.99	0.88	0.97	0.92	0.93	-0.87	0.85	0.91	0.84	0.95	0.98	0.97	0.68	0.96	0.98	0.68	0.6	0.95	-0.3	0.98	0.31	-0.02	0.93	-0.27	0.32

Click cells to compare fundamentals

Harrow Health Account Relationship Matchups

Harrow Health fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.1M	57.5M	98.3M	157.0M	311.8M	327.3M
Other Current Liab	2.4M	1.7M	4.9M	(836K)	27.0M	28.4M
Total Current Liabilities	12.3M	10.8M	9.7M	18.6M	49.3M	51.8M
Total Stockholder Equity	27.7M	27.2M	11.3M	27.2M	70.4M	73.9M
Net Debt	16.2M	19.4M	35.8M	7.9M	116.4M	122.2M
Retained Earnings	(74.0M)	(77.4M)	(95.4M)	(109.5M)	(133.9M)	(127.2M)
Cash	4.7M	4.1M	42.2M	96.3M	74.1M	77.8M
Cash And Short Term Investments	29.9M	32.6M	50.7M	96.3M	82.8M	86.9M
Common Stock Shares Outstanding	26.5M	25.9M	26.8M	27.5M	32.6M	34.2M
Liabilities And Stockholders Equity	59.1M	57.5M	98.3M	157.0M	311.8M	327.3M
Other Stockholder Equity	101.7M	104.6M	106.7M	136.7M	204.2M	214.4M
Total Liab	31.7M	30.6M	87.4M	130.1M	241.8M	253.8M
Total Current Assets	36.8M	40.1M	60.7M	118.3M	139.1M	146.0M
Accounts Payable	7.4M	3.6M	5.2M	18.6M	21.4M	22.5M
Non Current Liabilities Total	19.4M	19.8M	77.7M	111.5M	192.4M	202.0M
Other Current Assets	786K	941K	1.3M	22.0M	9.0M	9.4M
Property Plant And Equipment Net	11.9M	11.3M	9.1M	11.0M	10.3M	5.6M
Non Current Assets Total	22.3M	17.3M	37.7M	37.2M	172.7M	181.3M
Non Currrent Assets Other	7.7M	3.8M	12.4M	4.1K	(2.1M)	(2.0M)
Short Long Term Debt Total	21.0M	23.5M	78.0M	104.9M	190.5M	200.0M
Current Deferred Revenue	57K	66K	16K	113K	75K	71.3K
Short Term Debt	2.4M	5.1M	560K	723K	806K	765.7K
Accumulated Other Comprehensive Income	(2.8M)	(4.4M)	0.0	(409K)	(368.1K)	(386.5K)
Net Receivables	2.7M	2.7M	4.5M	6.4M	36.5M	38.3M
Short Term Investments	25.2M	28.5M	8.5M	5.6M	8.7M	10.8M
Inventory	3.3M	4.0M	4.2M	6.5M	10.9M	11.4M
Intangible Assets	2.3M	1.9M	17.1M	25.8M	162.0M	170.1M
Long Term Debt	12.2M	12.4M	71.7M	104.2M	119.8M	125.8M
Capital Surpluse	101.7M	104.6M	106.7M	137.1M	157.6M	113.7M
Property Plant Equipment	11.9M	11.3M	3.1M	3.5M	3.1M	5.7M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether Harrow Health 8625 is a strong investment it is important to analyze Harrow Health's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Harrow Health's future performance. For an informed investment choice regarding Harrow Stock, refer to the following important reports:

How To Invest In Harrow

Details

Is Harrow Stock a good investment?

Details

What is Harrow Health's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Harrow Health 8625. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing.

For more information on how to buy Harrow Stock please use our How to buy in Harrow Stock guide.

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Harrow Health. If investors know Harrow will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Harrow Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Return On Equity

0.4484

The market value of Harrow Health 8625 is measured differently than its book value, which is the value of Harrow that is recorded on the company's balance sheet. Investors also form their own opinion of Harrow Health's value that differs from its market value or its book value, called intrinsic value, which is Harrow Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Harrow Health's market value can be influenced by many factors that don't directly affect Harrow Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Harrow Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Harrow Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Harrow Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Harrow Net Income From Continuing Ops vs Cost Of Revenue Analysis

Net Income From Continuing Ops vs Cost Of Revenue

Net Income From Continuing Ops vs Cost Of Revenue Correlation Analysis

Correlation Coefficient

Net Income From Continuing Ops

Cost Of Revenue

Harrow Health fundamental ratios Correlations

Harrow Health Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Harrow Health fundamental ratios Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 1.0	Total Assets
Non Current Liabilities Total	+ 1.0	Total Liab
Short Long Term Debt Total	+ 1.0	Total Liab
Short Long Term Debt Total	+ 1.0	Non Current Liabilities Total
Net Receivables	+ 1.0	Non Current Assets Total
Non Current Liabilities Total	+ 0.99	Total Assets

Other Stockholder Equity	- 0.96	Retained Earnings
Common Stock Shares Outstanding	- 0.94	Retained Earnings
Inventory	- 0.87	Retained Earnings
Accounts Payable	- 0.85	Retained Earnings
Common Stock	- 0.84	Retained Earnings
Total Current Assets	- 0.84	Retained Earnings